search
Back to results

Gluten Reduction and Risk of Celiac Disease (GRAIN)

Primary Purpose

Celiac Disease in Children, Autoimmune Diseases, type1diabetes

Status
Recruiting
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Gluten reduced diet
Sponsored by
Lund University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Celiac Disease in Children focused on measuring gluten, diet

Eligibility Criteria

6 Months - 6 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • children screened positive for HLA DQ2/X (X is neither DQ2 or DQ8)
  • children who refused enrolment to the on-going study PreSiCe (ClinicalTrials.gov Identifier NCT03562221)

Exclusion Criteria:

  • congenital chronic disorder where intervention with diet may be affected
  • written informed consent from both caregivers are missing

Sites / Locations

  • Clinical Research Center (CRC), Bldng 60:11Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

No intervention

Gluten reduced diet

Arm Description

The group will be followed without any intervention, with regular visits at the research clinic.

Subjects will follow a diet that does not exceed a daily intake of 3 gram gluten. The group will be followed with regular visits at the research clinic.

Outcomes

Primary Outcome Measures

Celiac disease autoimmunity (CDA)
Children tested positive for tissue transglutaminase autoantibodies (tTGA) in two consecutive serum samples 3-6 months apart.

Secondary Outcome Measures

Celiac disease (CD)
celiac disease diagnosed, defined by intestinal biopsy showing a Marsh score of >2 or by high levels of tTGA with symptoms.

Full Information

First Posted
October 13, 2020
Last Updated
October 3, 2023
Sponsor
Lund University
search

1. Study Identification

Unique Protocol Identification Number
NCT04593888
Brief Title
Gluten Reduction and Risk of Celiac Disease
Acronym
GRAIN
Official Title
Gluten Reduction After Infancy and Risk of Celiac Disease Study
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 5, 2021 (Actual)
Primary Completion Date
December 31, 2025 (Anticipated)
Study Completion Date
December 31, 2035 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lund University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Celiac disease shares many features of other autoimmune diseases such as type 1 diabetes. Recently, it was published that higher amounts of gluten intake increased the risk for celiac disease. Optimal amounts of gluten to be introduced during weaning have not yet been established. The aim is to investigate if a gluten-restricted diet (e.g. below 3 gram per day) will reduce the risk of develop CDA and IA in genetically predisposed children by the age of 5 years. Children who screened positive for HLA DQ2/X (X is neither DQ2 nor DQ8) in the GPPAD-02 (ASTR1D [ClinicalTrials.gov Identifier NCT03316261]) screening will be contacted by a study nurse.
Detailed Description
Gluten is a complex mixture of proteins, mainly gliadin and glutenin, rich in proline and glutamine amino acids which make these proteins resistant to complete degradation by enzymes in the small intestinal. Intolerance to gluten leads to inflammation of the intestinal epithelium and villous atrophy, a disorder called celiac disease. Celiac disease shares many features of other autoimmune diseases such as type 1 diabetes (T1D). First, celiac disease is associated with certain HLA genotypes of whom 95% of all patients with celiac disease carry the haplotypes DQA1*0501-DQB1*0201 (abbreviated DQ2) and the reminder 5% DQA1*0301-DQB1*0302 (abbreviated DQ8). There is a gene dose effect of HLA-DQ on the risk of develop celiac disease; 20% of the children homozygous for HLA-DQ2/DQ2 will develop celiac disease by 10 years of age. Second, celiac disease is also strongly associated with the presence of autoantibodies directed against tissue transglutaminase (tTGA) that occurs in 100% of children with celiac disease. Timing of gluten introduction and breastfeeding duration have previously been proposed to influence risk for celiac disease. However, based on the results from the multinational birth cohort study The Environmental determinants of Diabetes in the Young (TEDDY) study and other observational studies, timing of gluten introduction seems not associated with celiac disease in genetically at-risk children. In an RCT, introduction of small amounts of gluten at the age of 4-6 months did not reduce the risk for celiac disease by the age of 3 years in genetically at-risk children. Current international infant feeding recommendations recommend that gluten is introduced into the infant's diet anytime between 4-12 months of age and that consumption of large quantities of gluten should be avoided during the first month after gluten introduction and during infancy. Recently, the TEDDY study published that higher amounts of gluten intake increased the risk for celiac disease, which have been confirmed in two other observational cohort studies. In the TEDDY study, daily gluten intake was associated with higher increased risk of developing persistently positive tTGA, a definition coined celiac disease autoimmunity (CDA), as well as with celiac disease for every 1-g/day increase in gluten intake. Optimal amounts of gluten to be introduced during weaning have not yet been established. It is well known that an overlap between celiac disease and T1D exists most likely due to shared genetic risks of HLA-DQ2 and/or DQ8 in both disorders. Prospective studies in infants genetically predisposed to T1D and celiac disease showed that antibody positivity to both disorders begins in the first 1-3 years of life. The study aim is to investigate if a gluten-restricted diet will reduce the risk of develop CDA and IA in genetically predisposed children by the age of 5 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Celiac Disease in Children, Autoimmune Diseases, type1diabetes
Keywords
gluten, diet

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Masking Description
study participants will be randomized to either the "gluten-reduced" or "no intervention" arm on-going after enrolment.
Allocation
Randomized
Enrollment
2000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
No intervention
Arm Type
No Intervention
Arm Description
The group will be followed without any intervention, with regular visits at the research clinic.
Arm Title
Gluten reduced diet
Arm Type
Experimental
Arm Description
Subjects will follow a diet that does not exceed a daily intake of 3 gram gluten. The group will be followed with regular visits at the research clinic.
Intervention Type
Behavioral
Intervention Name(s)
Gluten reduced diet
Intervention Description
Dietary advice focusing on reducing gluten intake in children
Primary Outcome Measure Information:
Title
Celiac disease autoimmunity (CDA)
Description
Children tested positive for tissue transglutaminase autoantibodies (tTGA) in two consecutive serum samples 3-6 months apart.
Time Frame
from 6 months of age up until 10 years of age
Secondary Outcome Measure Information:
Title
Celiac disease (CD)
Description
celiac disease diagnosed, defined by intestinal biopsy showing a Marsh score of >2 or by high levels of tTGA with symptoms.
Time Frame
from 6 months of age up until 10 years of age
Other Pre-specified Outcome Measures:
Title
Islet autoimmunity
Description
Children tested positive for typ1 1 diabetes related autoantibodies (IAA, GADA, IA2A) in two consecutive serum samples 3-6 months apart.
Time Frame
from 6 months of age up until 10 years of age

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
6 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: children screened positive for HLA DQ2/X (X is neither DQ2 or DQ8) children who refused enrolment to the on-going study PreSiCe (ClinicalTrials.gov Identifier NCT03562221) Exclusion Criteria: congenital chronic disorder where intervention with diet may be affected written informed consent from both caregivers are missing
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Carin Andrén Aronsson, PhD
Phone
+46 40391113
Email
carin.andren_aronsson@med.lu.se
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daniel Agardh, MD, PhD
Organizational Affiliation
Lund University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinical Research Center (CRC), Bldng 60:11
City
Malmö
ZIP/Postal Code
20502
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carin Andrén Aronsson, PhD
Phone
+46 40391113
Email
carin.andren_aronsson@med.lu.se

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
31408136
Citation
Andren Aronsson C, Lee HS, Hard Af Segerstad EM, Uusitalo U, Yang J, Koletzko S, Liu E, Kurppa K, Bingley PJ, Toppari J, Ziegler AG, She JX, Hagopian WA, Rewers M, Akolkar B, Krischer JP, Virtanen SM, Norris JM, Agardh D; TEDDY Study Group. Association of Gluten Intake During the First 5 Years of Life With Incidence of Celiac Disease Autoimmunity and Celiac Disease Among Children at Increased Risk. JAMA. 2019 Aug 13;322(6):514-523. doi: 10.1001/jama.2019.10329.
Results Reference
result
PubMed Identifier
31082869
Citation
Marild K, Dong F, Lund-Blix NA, Seifert J, Baron AE, Waugh KC, Taki I, Stordal K, Tapia G, Stene LC, Johnson RK, Liu E, Rewers MJ, Norris JM. Gluten Intake and Risk of Celiac Disease: Long-Term Follow-up of an At-Risk Birth Cohort. Am J Gastroenterol. 2019 Aug;114(8):1307-1314. doi: 10.14309/ajg.0000000000000255.
Results Reference
result
PubMed Identifier
25271603
Citation
Vriezinga SL, Auricchio R, Bravi E, Castillejo G, Chmielewska A, Crespo Escobar P, Kolacek S, Koletzko S, Korponay-Szabo IR, Mummert E, Polanco I, Putter H, Ribes-Koninckx C, Shamir R, Szajewska H, Werkstetter K, Greco L, Gyimesi J, Hartman C, Hogen Esch C, Hopman E, Ivarsson A, Koltai T, Koning F, Martinez-Ojinaga E, te Marvelde C, Pavic A, Romanos J, Stoopman E, Villanacci V, Wijmenga C, Troncone R, Mearin ML. Randomized feeding intervention in infants at high risk for celiac disease. N Engl J Med. 2014 Oct 2;371(14):1304-15. doi: 10.1056/NEJMoa1404172.
Results Reference
result
PubMed Identifier
25271602
Citation
Lionetti E, Castellaneta S, Francavilla R, Pulvirenti A, Tonutti E, Amarri S, Barbato M, Barbera C, Barera G, Bellantoni A, Castellano E, Guariso G, Limongelli MG, Pellegrino S, Polloni C, Ughi C, Zuin G, Fasano A, Catassi C; SIGENP (Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition) Working Group on Weaning and CD Risk. Introduction of gluten, HLA status, and the risk of celiac disease in children. N Engl J Med. 2014 Oct 2;371(14):1295-303. doi: 10.1056/NEJMoa1400697.
Results Reference
result
PubMed Identifier
26453955
Citation
Andren Aronsson C, Lee HS, Koletzko S, Uusitalo U, Yang J, Virtanen SM, Liu E, Lernmark A, Norris JM, Agardh D; TEDDY Study Group. Effects of Gluten Intake on Risk of Celiac Disease: A Case-Control Study on a Swedish Birth Cohort. Clin Gastroenterol Hepatol. 2016 Mar;14(3):403-409.e3. doi: 10.1016/j.cgh.2015.09.030. Epub 2015 Nov 25.
Results Reference
result

Learn more about this trial

Gluten Reduction and Risk of Celiac Disease

We'll reach out to this number within 24 hrs